BC Extra | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) appointed Margaret Hamburg to its board, effective Jan. 10, 2019. Hamburg is president-elect of the American Association for the Advancement of Science (AAAS), foreign secretary of the National...
BC Extra | Sep 10, 2018
Company News

Management tracks: PolarityTE, Medivir

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:COOL) terminated Chief Investment Officer and EVP John Stetson on Friday after the Securities and Exchanges Commission filed charges against him alleging his involvement in "pump-and-dump" schemes (see "Opko's Frost...
BC Extra | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

Cancer company Verastem Inc. (NASDAQ:VSTM) named NgocDiep Le CMO. She was VP of immuno-oncology innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB (Stockholm, Sweden) named Bastian...
BC Extra | Jul 15, 2017
Company News

Management tracks

Immunotherapy company Advaxis Inc. (NASDAQ:ADXS) said President and CEO Daniel O’Connor resigned. CBO Anthony Lombardo will be interim CEO while the company seeks a replacement. Rare disease company OxThera AB (Stockholm, Sweden) named Matthew Gantz...
BC Week In Review | Dec 2, 2016
Financial News

OxThera completes venture financing

OxThera raised €32 million ($34.1 million) in a round co-led by LSP, Ysios Capital, Sunstone Capital and Flerie Invest. Existing investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet also participated. OxThera AB , Uppsala, Sweden ...
BC Extra | Dec 1, 2016
Financial News

OxThera raises EUR 32M

OxThera AB (Uppsala, Sweden) raised EUR 32 million ($34.1 million) in a round co-led by LSP, Ysios Capital, Sunstone Capital and Flerie Invest. Also participating were existing investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and...
BC Week In Review | Sep 29, 2014
Clinical News

Oxabact regulatory update

The European Commission granted Orphan Drug designation to Oxabact from OxThera to treat short bowel syndrome (SBS). The capsule formulation of lyophilized live Oxalobacter formigenes has Orphan Drug designation in the EU and U.S. to...
BC Week In Review | Apr 21, 2014
Financial News

OxThera completes venture financing

OxThera AB , Uppsala, Sweden   Business: Endocrine/Metabolic   Date completed: 4/16/14   Type: Venture financing   Raised: SEK70 million ($10.7 million)   Investors: Kurma Partners; Idinvest Partners; Mayo Clinic ; existing investors  ...
BC Week In Review | Feb 17, 2014
Company News

OxThera board of directors update

OxThera AB , Uppsala, Sweden   Business: Endocrine/Metabolic   Appointed: Georges Gemayel as chairman  ...
BC Week In Review | Jan 20, 2014
Clinical News

Oxabact: Phase I/II started

OxThera began the double-blind, placebo-controlled, European Phase I/II OC5-DB-01 trial to evaluate twice-daily oral Oxabact in 24 patients with primary hyperoxaluria. Oxabact has Orphan Drug designation for the indication in the EU and U.S. OxThera...
Items per page:
1 - 10 of 19
BC Extra | Oct 10, 2018
Company News

Management tracks: Hamburg joins Alnylam board

RNAi therapeutics company Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) appointed Margaret Hamburg to its board, effective Jan. 10, 2019. Hamburg is president-elect of the American Association for the Advancement of Science (AAAS), foreign secretary of the National...
BC Extra | Sep 10, 2018
Company News

Management tracks: PolarityTE, Medivir

Regenerative biomaterial company PolarityTE Inc. (NASDAQ:COOL) terminated Chief Investment Officer and EVP John Stetson on Friday after the Securities and Exchanges Commission filed charges against him alleging his involvement in "pump-and-dump" schemes (see "Opko's Frost...
BC Extra | Oct 13, 2017
Company News

Management tracks: Verastem, OxThera

Cancer company Verastem Inc. (NASDAQ:VSTM) named NgocDiep Le CMO. She was VP of immuno-oncology innovative medicines at the MedImmune LLC subsidiary of AstraZeneca plc (LSE:AZN; NYSE:AZN). Rare disease company OxThera AB (Stockholm, Sweden) named Bastian...
BC Extra | Jul 15, 2017
Company News

Management tracks

Immunotherapy company Advaxis Inc. (NASDAQ:ADXS) said President and CEO Daniel O’Connor resigned. CBO Anthony Lombardo will be interim CEO while the company seeks a replacement. Rare disease company OxThera AB (Stockholm, Sweden) named Matthew Gantz...
BC Week In Review | Dec 2, 2016
Financial News

OxThera completes venture financing

OxThera raised €32 million ($34.1 million) in a round co-led by LSP, Ysios Capital, Sunstone Capital and Flerie Invest. Existing investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and Brohuvudet also participated. OxThera AB , Uppsala, Sweden ...
BC Extra | Dec 1, 2016
Financial News

OxThera raises EUR 32M

OxThera AB (Uppsala, Sweden) raised EUR 32 million ($34.1 million) in a round co-led by LSP, Ysios Capital, Sunstone Capital and Flerie Invest. Also participating were existing investors Kurma Partners, Idinvest Partners, Stiftelsen Industrifonden and...
BC Week In Review | Sep 29, 2014
Clinical News

Oxabact regulatory update

The European Commission granted Orphan Drug designation to Oxabact from OxThera to treat short bowel syndrome (SBS). The capsule formulation of lyophilized live Oxalobacter formigenes has Orphan Drug designation in the EU and U.S. to...
BC Week In Review | Apr 21, 2014
Financial News

OxThera completes venture financing

OxThera AB , Uppsala, Sweden   Business: Endocrine/Metabolic   Date completed: 4/16/14   Type: Venture financing   Raised: SEK70 million ($10.7 million)   Investors: Kurma Partners; Idinvest Partners; Mayo Clinic ; existing investors  ...
BC Week In Review | Feb 17, 2014
Company News

OxThera board of directors update

OxThera AB , Uppsala, Sweden   Business: Endocrine/Metabolic   Appointed: Georges Gemayel as chairman  ...
BC Week In Review | Jan 20, 2014
Clinical News

Oxabact: Phase I/II started

OxThera began the double-blind, placebo-controlled, European Phase I/II OC5-DB-01 trial to evaluate twice-daily oral Oxabact in 24 patients with primary hyperoxaluria. Oxabact has Orphan Drug designation for the indication in the EU and U.S. OxThera...
Items per page:
1 - 10 of 19